Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
KEATING LAURIE | EVP, Chief Legal Officer | Jan 13 | Option Exercise | 82.45 | 9,027 | 744,290 | 11,261 | Jan 15 04:03 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jan 13 | Sale | 169.90 | 9,027 | 1,533,698 | 2,234 | Jan 15 04:03 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jan 12 | Option Exercise | 72.83 | 14,941 | 1,088,149 | 17,175 | Jan 13 04:05 PM | Greenstreet Yvonne | President & COO | Jan 12 | Option Exercise | 42.22 | 3,125 | 131,938 | 7,945 | Jan 13 04:04 PM | Greenstreet Yvonne | President & COO | Jan 12 | Sale | 161.00 | 3,125 | 503,125 | 4,820 | Jan 13 04:04 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jan 12 | Sale | 160.20 | 14,941 | 2,393,619 | 2,234 | Jan 13 04:05 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jan 11 | Sale | 154.00 | 758 | 116,732 | 2,234 | Jan 13 04:05 PM | PAUL STEVEN M | Director | Dec 18 | Option Exercise | 9.30 | 15,000 | 139,500 | 16,000 | Dec 22 04:02 PM | PAUL STEVEN M | Director | Dec 18 | Sale | 140.00 | 15,000 | 2,100,000 | 1,000 | Dec 22 04:02 PM | SHARP PHILLIP A | Director | Nov 25 | Option Exercise | 9.30 | 30,000 | 279,000 | 265,633 | Nov 30 04:03 PM | SHARP PHILLIP A | Director | Nov 25 | Sale | 124.89 | 30,000 | 3,746,749 | 235,633 | Nov 30 04:03 PM | MARAGANORE JOHN | Chief Executive Officer | Nov 19 | Option Exercise | 9.14 | 34,765 | 317,752 | 232,354 | Nov 20 04:02 PM | MARAGANORE JOHN | Chief Executive Officer | Nov 19 | Sale | 124.23 | 34,765 | 4,319,025 | 197,589 | Nov 20 04:02 PM | Vaishnaw Akshay | President, R&D | Sep 29 | Option Exercise | 42.22 | 971 | 40,996 | 15,090 | Oct 01 04:03 PM | Vaishnaw Akshay | President, R&D | Sep 29 | Sale | 140.00 | 971 | 135,940 | 14,119 | Oct 01 04:03 PM | Greene Barry E | President | Sep 09 | Option Exercise | 9.14 | 44,530 | 407,004 | 114,873 | Sep 11 05:11 PM | Greene Barry E | President | Sep 09 | Sale | 123.23 | 44,530 | 5,487,594 | 70,343 | Sep 11 05:11 PM | MARAGANORE JOHN | Chief Executive Officer | Aug 20 | Option Exercise | 9.14 | 34,765 | 317,752 | 232,354 | Aug 21 04:06 PM | MARAGANORE JOHN | Chief Executive Officer | Aug 20 | Sale | 136.13 | 34,765 | 4,732,542 | 197,589 | Aug 21 04:06 PM | Greene Barry E | President | Aug 10 | Option Exercise | 70.95 | 4,931 | 349,871 | 67,167 | Aug 11 04:09 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jul 13 | Option Exercise | 87.16 | 35,750 | 3,116,066 | 50,242 | Jul 14 04:03 PM | KEATING LAURIE | EVP, Chief Legal Officer | Jul 13 | Sale | 160.67 | 47,250 | 7,591,790 | 2,992 | Jul 14 04:03 PM | Greenstreet Yvonne | Chief Operating Officer | Jul 10 | Option Exercise | 77.10 | 46,639 | 3,595,867 | 51,459 | Jul 14 04:02 PM | Greenstreet Yvonne | Chief Operating Officer | Jul 10 | Sale | 161.00 | 46,639 | 7,508,879 | 4,820 | Jul 14 04:02 PM | Greenstreet Yvonne | Chief Operating Officer | Jul 09 | Option Exercise | 43.14 | 11,236 | 484,743 | 16,056 | Jul 10 04:03 PM | Greenstreet Yvonne | Chief Operating Officer | Jul 09 | Sale | 161.00 | 11,236 | 1,808,996 | 4,820 | Jul 10 04:03 PM | Greene Barry E | President | Jul 07 | Option Exercise | 9.14 | 22,265 | 203,502 | 84,501 | Jul 09 04:02 PM | Greene Barry E | President | Jul 07 | Sale | 159.99 | 22,265 | 3,562,177 | 62,236 | Jul 09 04:02 PM | Vaishnaw Akshay | President, R&D | Jun 22 | Option Exercise | 42.22 | 970 | 40,953 | 15,089 | Jun 24 04:02 PM | Vaishnaw Akshay | President, R&D | Jun 22 | Sale | 151.07 | 970 | 146,536 | 14,119 | Jun 24 04:02 PM | MARAGANORE JOHN | Chief Executive Officer | May 20 | Option Exercise | 9.14 | 34,765 | 317,752 | 232,354 | May 22 04:03 PM | MARAGANORE JOHN | Chief Executive Officer | May 20 | Sale | 143.22 | 34,765 | 4,978,983 | 197,589 | May 22 04:03 PM | Greenstreet Yvonne | Chief Operating Officer | May 06 | Option Exercise | 77.10 | 50,000 | 3,855,000 | 54,820 | May 07 04:08 PM | Greene Barry E | President | May 06 | Option Exercise | 9.14 | 22,265 | 203,502 | 84,501 | May 07 04:09 PM | Greene Barry E | President | May 06 | Sale | 149.99 | 22,265 | 3,339,527 | 62,236 | May 07 04:09 PM | Greenstreet Yvonne | Chief Operating Officer | May 06 | Sale | 150.00 | 50,000 | 7,500,000 | 4,820 | May 07 04:08 PM | Greenstreet Yvonne | Chief Operating Officer | May 05 | Option Exercise | 42.22 | 7,811 | 329,780 | 12,631 | May 07 04:08 PM | Greenstreet Yvonne | Chief Operating Officer | May 05 | Sale | 140.00 | 7,811 | 1,093,540 | 4,820 | May 07 04:08 PM | Vaishnaw Akshay | President, R&D | Apr 20 | Option Exercise | 42.22 | 21,971 | 927,616 | 36,090 | Apr 22 04:06 PM | KEATING LAURIE | EVP, Chief Legal Officer | Apr 20 | Option Exercise | 77.40 | 10,000 | 774,000 | 24,492 | Apr 22 04:07 PM | Vaishnaw Akshay | President, R&D | Apr 20 | Sale | 140.00 | 21,971 | 3,075,940 | 14,119 | Apr 22 04:06 PM | KEATING LAURIE | EVP, Chief Legal Officer | Apr 20 | Sale | 139.00 | 10,000 | 1,390,000 | 14,492 | Apr 22 04:07 PM |
|